While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > FY2020 Drug Pricing Reform
FY2020 Drug Pricing Reform
-
Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
-
Up-to-5-Band Plan OK’ed for Unreasonable Generic Price Rises, Change to Affect Single Price Band Rule Too
December 16, 2019
-
Chuikyo Settles on “Third Price Revision” for Expansion of Comparator PMP Deduction Rule
December 16, 2019
-
Chuikyo Pushes Up-to-5-Band Plan to Address Unreasonable Generic Price Rises, Prods Industry Reorganization
December 9, 2019
-
US, European Trade Groups Oppose Tighter Re-Pricing Rules
December 9, 2019
-
Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
-
Average NHI-Market Price Gap at 8.0%, Suspected Bid-Rigging Data Excluded: Chuikyo
December 4, 2019
-
MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
-
Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
-
MHLW Wants to Subject Innovative Add’l Use to PMP, but No Price Raise
November 25, 2019
-
MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
-
Industry Urges Careful Approach to Creating Special Rule for Indication Change Re-Pricing: Chuikyo
November 25, 2019
-
No Change to Essential Drug Rule in 2020 Reform: MHLW
November 25, 2019
-
MHLW Proposes Earlier Price Cuts for Off-Patent Drugs with 80%-Plus Gx Rates, but Chuikyo Questions 2-Year Grace Period
November 25, 2019
-
MHLW Proposes Continued Discussions for Cell & Gene Therapy Pricing
November 25, 2019
-
MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
-
Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
-
MHLW Sees No Major Problem with Current Rules for Low-Price Products, Chuikyo Questions Price Negotiation Process
November 12, 2019
-
Chuikyo Positive about Changing Rules to Set Sales Thresholds after Market Expansion Re-Pricing Applied
November 11, 2019
-
Japan to Use September 2019 Market Price Data for 2020 Revisions, April 2018 NHI Prices as Baseline
November 11, 2019
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…